Johannes Nippgen

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.8K citations · Full text

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

David A. Reardon, Karen Fink, Tom Mikkelsen et al. · Journal of Clinical Oncology · 2008 · 470 citations · Full text

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

Eric Van Cutsem, Marek P. Nowacki, István Láng et al. · Journal of Clinical Oncology · 2007 · 314 citations

Pathology, Pharmacotherapy, Crystal Trial +17

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Journal of Clinical Oncology · 2008 · 241 citations

Kras Mutations, Surgical Oncology, Gastrointestinal Oncology +15

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Jan M. Langrehr, Helmut Oettle, Jochen Raedle et al. · BMC Cancer · 2006 · 122 citations · Full text